Du är här

2014-04-30

Ablynx: PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")

REGULATED INFORMATION

GHENT, Belgium, 30 April 2014 -
Ablynx[Euronext Brussels: ABLX]

,
today announced, in accordance with Article 14 of the Belgian Law of 2 May
2007 regarding the publication of major shareholdings in issuers whose
securities are admitted to trading on a regulated market (the "Transparency
Law"), that it received a notification of shareholdings from Abingworth
Management Limited and Abingworth LLP.

Abingworth Management Limited and Abingworth LLP notified that they have
dropped below the 10% threshold (from 10.01% to 9.99%) as a result of the
warrant exercise by some employees and consultants of the Company, which was
announced on 23 April 2014.

Full versions of all transparency notifications are available on the website
of Ablynx, under the sectionInvestors.

About Ablynx

Ablynxis a biopharmaceutical company engaged in the discovery and development
ofNanobodies®, a novel class of therapeutic proteins based on single-domain
antibody fragments, for a range of serious human diseases, including
inflammation, haematology, oncology and pulmonary disease. Today, the Company
has approximately30 programmes in the pipelineand seven Nanobodies at
clinical development stage. Ablynx has ongoing research collaborations and
significant partnerships with major pharmaceutical companies including
AbbVie, Boehringer Ingelheim, Merck&Co, Merck Serono and Novartis. The
Company is headquartered in Ghent, Belgium. More information can be found
onwww.ablynx.com.

For more information, please contact

Ablynx:

Dr Edwin Moses
CEO
t: +32 (0)9 262 00 07
m: +44 (0)7771 954 193 /
+32 (0)473 39 50 68
e: edwin.moses@ablynx.com

Marieke Vermeersch
Associate Director Investor Relations
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e: marieke.vermeersch@ablynx.com

Follow us on Twitter @AblynxABLX

Ablynx media relations
Consilium Strategic Communications:

Mary-Jane Elliott, Amber Bielecka, Lindsey Neville
t: +44 203 709 5700
e: ablynx@consilium-comms.com

pdf version of the press release
http://hugin.info/137912/R/1781776/609730.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Ablynx via Globenewswire

HUG#1781776

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.